ALK-Abelló Signs Partnership Agreement with Schering-Plough

ALK-Abelló A/S has signed an agreement with Schering-Plough on a strategic alliance to develop and commercialise ALK-Abelló's tablet-based allergy immunotherapies in the USA, Canada and Mexico. The agreement gives Schering-Plough exclusive licence rights to develop, market and distribute the tablet-based immunotherapies against grass pollen allergy, GRAZAX, house dust mite allergy, and ragweed allergy.

Under the agreement, ALK-Abello will receive an upfront payment and milestone payments relating to clinical development and regulatory events for the three tablet-based allergy immunotherapy compounds. In addition, there are various sales milestone payments. The total value of all these potential payments could exceed EUR 194 million.

Furthermore, ALK-Abelló will be entitled to royalty payments on net sales of the products by Schering-Plough. Schering-Plough will be responsible for all costs of clinical development, registration, marketing and sales of the products in the markets covered by this agreement. ALK-Abelló will be responsible for tablet production and supply.

For further information please contact:

Jacob Frische,

Director

Tel: +45 45 74 75 51

Email: jaf@dk.alk-abello.com

Or visit: www.alk-abello.com